Brain Neoplasm Clinical Trial
Official title:
Surgical Resection of Latent Brain Tumors Prior to Recurrence
Verified date | February 2024 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial evaluates the side effects and possible benefits of operating on brain tumors prior to the tumor coming back (recurrence). Understanding when surgery is most useful to patients with brain tumors is important. Some patients may undergo chemotherapy or radiation but still have visible tumor remaining after treatment. The purpose of this research is to compare outcomes of those who have surgery after chemotherapy or radiation, but prior to tumor recurrence, to those who have surgery at a different time, or no surgery at all.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | March 1, 2026 |
Est. primary completion date | March 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age >= 18 years - Histological or cytological confirmation of brain tumor and/or suspected brain tumor based on clinical and radiologic findings - Prior chemotherapy and/or radiation treatment directed to the known/suspected tumor - Radiographic evidence of residual or previously unresected tumor - Willingness to undergo surgery and sign informed consent - Patients not currently eligible for an alternate competing interventional clinical trial - Enrollment in the Mayo Clinic Cancer Center Neuro-Oncology Program Registry for the study of Nervous System Tumors (IRB#12-003458) Exclusion Criteria: - Age < 18 years - Found to be a member of a vulnerable population (e.g. pregnant, lacking capacity to consent) during the course of pre-enrollment or pre-surgical assessment - Prior gross total resection of brain tumor leading to absence of visible latent disease (exemption available for post-operative enrollment) - Any contraindication to surgery, including anyone who in the opinion of the surgeon is at unreasonably elevated risk of wound complications - Avastin within the past 6 months for any reason - Patients who have not yet undergone surgery or radiation, but who would be appropriate candidates for an alternate interventional clinical trial (e.g. post-operative fractionated vs single fraction radiation to the surgical cavity for surgical brain mets) |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic in Rochester | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility of surgical resection by short and long term outcomes | Feasibility will be evaluated by meeting enrollment criteria. | Up to 5 years | |
Primary | Incidence of adverse events | Safety will be evaluated by recording adverse events utilizing proper reporting measures. | Up to 5 years | |
Secondary | Overall survival | Median time of survival along with 95% confidence interval will be estimated using the Kaplan-Meier method. | Time from initial diagnosis to the date of death/or censored at the time of last known alive, assessed up to 5 years | |
Secondary | Progression free survival | Median time of progress-free survival along with the 95% confidence interval will be estimated using the Kaplan Meier method. | Time from initial diagnosis to the date progression is identified, assessed up to 5 years | |
Secondary | Neurosurgical morbidity | Postoperative complications such as wound infection and neurologic deficits will be logged. Additional metrics including hospital stay and readmission rates will also be logged. Standard descriptive statistics will be used to summarize the outcomes. | Up to completion of surgery | |
Secondary | Time to subsequent treatment (i.e. chemotherapy/immunotherapy and/or radiation) | Median time to subsequent treatment along with the 95% confidence interval will be estimated using standard descriptive statistics. | Time from surgical resection at Mayo Clinic until an adjuvant treatment is administered, assessed up to 5 years | |
Secondary | Rate of local recurrence | Will be logged as a categorical value and continuous data - endpoint is diagnosis of local recurrent disease. The presence and time to local recurrent disease will be logged and standard descriptive statistics will be used to summarize the outcomes. | Up to 5 years | |
Secondary | Rate of leptomeningeal disease | Will be logged as both a categorical value and continuous data - endpoint is diagnosis of leptomeningeal disease. The presence and time to occurrence of leptomeningeal disease will be logged and standard descriptive statistics will be used to summarize the outcomes. | Up to 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00001972 -
PET Scan of Brain Metabolism in Relation to Age and Disease
|
N/A | |
Completed |
NCT02798406 -
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
|
Phase 2 | |
Terminated |
NCT02855086 -
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
|
Phase 1/Phase 2 | |
Terminated |
NCT00638963 -
Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2)
|
Phase 2 | |
Withdrawn |
NCT03234309 -
Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors
|
Phase 2 | |
Completed |
NCT00178295 -
Radiation-Induced Cytokine Cascades and Their Correlation With Central Nervous System Injury
|
N/A | |
Recruiting |
NCT02800486 -
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
|
Phase 2 | |
Completed |
NCT01621295 -
Assessing the Patient Experience in Cancer Care
|
N/A | |
Completed |
NCT02964416 -
Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery
|
Phase 4 | |
Completed |
NCT00001574 -
A Pilot Study of 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Pediatric Patients With Primary and Metastatic Brain Tumors
|
||
Recruiting |
NCT02861898 -
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT00040573 -
Safety and Tolerability Study of 131I-TM-601 to Treat Adult Patients With Recurrent Glioma.
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04553757 -
Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
|
||
Recruiting |
NCT02754544 -
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
|
N/A | |
Recruiting |
NCT03216148 -
18F-FET PET in Childhood Brain Tumours
|
Phase 2 | |
Completed |
NCT00001171 -
Evaluation of Factors in Human Brain Tumors
|
N/A | |
Withdrawn |
NCT01413438 -
Bevacizumab With or Without Surgery for Adult Glioblastomas
|
Phase 2 | |
Not yet recruiting |
NCT05516485 -
Measuring Brain Tumor Consistency Using Magnetic Resonance Elastography
|
N/A | |
Recruiting |
NCT02639325 -
Tumor Related Epilepsy
|
||
Recruiting |
NCT02672995 -
Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial
|
Phase 1 |